Potential biomarkers of early pancreatic cancer discovered
the ONA take:
Patients with pancreatic cancer face a poor prognosis, as only approximately 6% of patients with pancreatic cancer survive more than 5 years after diagnosis.
The low survival rate is primarily because no reliable tools are available to make an early diagnosis, when tumors can be removed before they metastasize. A team at H. Lee Moffitt Cancer Center, in Tampa, Florida, may have found a potential biomarker for the disease.
Similar to ongoing work at other research centers, the Moffitt team is focusing on microRNAs, small molecules that control many cancer processes in the body.
The Moffitt team focused specifically on microRNAs linked to intraductal papillary mucinous neoplasms (IPMNs). IPMNs are a type of pancreatic cyst or lesion that can develop into pancreatic cancer the same way precancerous polyps in the colon develop into colon cancer.
These lesions can be seen on CT or MRI; however, imaging studies cannot determine if the lesions are benign or malignant. In addition, surgical resection of the lesions for biopsy can result in long-term diabetes or death. The Moffitt team identified six microRNAs that appeared to differentiate high-risk from low-risk lesions; they also appear to contribute to pancreatic cancer progression.
Researchers are hopeful that these findings will contribute to new ways of detecting the disease earlier and improving the poor prognosis for these patients.
Patients with pancreatic cancer face a poor prognosis, as only approximately 6% of patients survive.
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Costs, Complications Higher for Women Who Undergo Second Surgery After BCS
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression
- Assessment of Stromal Features in DCIS Requires Robustness
- Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|